Pluri Inc.
$3.59
▼
-0.9%
2026-04-21 08:52:01
www.pluri-biotech.com
NCM: PLUR
Explore Pluri Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$36.08 M
Current Price
$3.59
52W High / Low
$7.13 / $2.82
Stock P/E
—
Book Value
$-1.46
Dividend Yield
—
ROCE
-348.95%
ROE
669.52%
Face Value
—
EPS
$-3.31
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
127
Beta
0.72
Debt / Equity
-4.98
Current Ratio
0.43
Quick Ratio
0.68
Forward P/E
-1.75
Price / Sales
24.92
Enterprise Value
$61.22 M
EV / EBITDA
-2.5
EV / Revenue
45.72
Rating
None
Target Price
$12
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Alumis Inc. | $24.71 | — | $3.18 B | — | -134.01% | -86.68% | $30.6 / $2.76 | $2.88 |
| 2. | ImmunityBio, Inc. | $8.01 | — | $8.28 B | — | -58.17% | 71.02% | $12.43 / $1.83 | $-0.49 |
| 3. | Indaptus Therapeutics, Inc. | $3.61 | — | $7.74 M | — | -629.32% | -5.88% | $19.91 / $1.51 | $1.45 |
| 4. | Entera Bio Ltd. | $1.34 | — | $62.47 M | — | -83.6% | -1.08% | $3.22 / $0.91 | $0.28 |
| 5. | Alector, Inc. | $2.71 | — | $298.53 M | — | -69.73% | -1.82% | $3.4 / $0.9 | $0.28 |
| 6. | Precision BioSciences, Inc. | $7.58 | — | $187.43 M | — | -35.84% | -62.71% | $8.82 / $3.53 | $3.83 |
| 7. | Citius Pharmaceuticals, Inc. | $0.87 | — | $19.56 M | — | -44.79% | -47.85% | $2.48 / $0.63 | $3.57 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.2 M | 0.32 M | 0.4 M | 0.43 M | 0.18 M | — |
| Operating Profit | -6.51 M | -6.35 M | -6.62 M | -5.4 M | -4.96 M | — |
| Net Profit | -6.54 M | -5.85 M | -7.6 M | -6.15 M | -2.96 M | — |
| EPS in Rs | -0.65 | -0.58 | -0.76 | -0.61 | -0.29 | -1.08 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 1.34 M | 0.33 M | 0.29 M | 0.23 M |
| Operating Profit | -22.18 M | -22.16 M | -27.25 M | -41.59 M |
| Net Profit | -22.58 M | -20.89 M | -28.32 M | -41.24 M |
| EPS in Rs | -2.25 | -2.08 | -2.82 | -4.1 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 38.68 M | 39.53 M | 50.8 M | 68.06 M |
| Total Liabilities | 39.55 M | 34.11 M | 35.5 M | 35.88 M |
| Equity | -6.84 M | 0.1 M | 13.36 M | 30.04 M |
| Current Assets | 22.09 M | 31.11 M | 41.41 M | 57.75 M |
| Current Liabilities | 32.33 M | 4.45 M | 5.62 M | 6.83 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -18.21 M | -18.02 M | -22.86 M | -36.5 M |
| Investing CF | 8.03 M | 10.58 M | 9.7 M | 11.78 M |
| Financing CF | 9.53 M | 8.84 M | 8.02 M | 7.5 M |
| Free CF | -19.83 M | -18.34 M | -23.12 M | -36.78 M |
| Capex | -1.62 M | -0.32 M | -0.26 M | -0.28 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 13.59% | 22.65% | — | — |
| Earnings Growth % | 26.25% | 31.33% | — | — |
| Profit Margin % | -6407.36% | -9867.94% | -17624.79% | — |
| Operating Margin % | -6796.93% | -9493.38% | -17774.79% | — |
| Gross Margin % | 98.77% | 96.86% | 100% | — |
| EBITDA Margin % | -6203.99% | -9645.3% | -16852.14% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-04-01 | 1:0.125 |